Fw: Hep C Inhibitor PSI-7977 Goes Interferon-Free in Phase III Studies

[Guest guest]

News on the new interferon free studies. Read other article I sent that is an update on the studies. Unfortuately, there has been serious relapse issue.

HepMag.com Email To A Friend...

Email to a friend

Hep C Inhibitor PSI-7977 Goes Interferon-Free in Phase III Studies

Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage clinical trials exploring the drug’s safety and efficacy as a component of a regimen that only needs to be taken for three months and that doesn’t include pegylated interferon, according to a November 1 announcement by the company. If all goes well in the studies, the company will petition the U.S. Food and Drug Administration (FDA) to begin the process of reviewing PSI-7977 for approval sometime in the second half of 2013.

Read More

For more news from HepMag.com please visit

HepMag.com.